Prostate-specific antigen: its clinical use and application in screening for prostate cancer

References

• McCormack R T, Rittenhouse H G, Finlay J A, Sokoloff R L, Wang T J, Wolfert R L, Lilja H, Oesterling J E. Molecular forms of Prostate-specific antigen (PSA) and the human kallekrein gene family: a new era. Accepted for publication as ‘clinical review’ Urology 1995
   Google Scholar
• Wu J T. Assay for prostate specific antigen (PSA): problems and possible solutions. J. Clin. Lab. Anal. 1994; 8: 51–62
   PubMed Web of Science ®Google Scholar
• Bangma ChrH, Blijenberg B G, Schröder F H. Single and serial PSA determinations in detection and follow-up of prostate cancer. 1995, E.U.A. Update seriesaccepted for publication.
   Google Scholar
• Lloyd S N, Collin G N, McKelvie G B, Hehir M, Rogers A C. Predicted and actual change in serum PSA following prostatectomy for BPH. Urology Apr, 1994; 43(4)472–9
   PubMedGoogle Scholar
• Hammerer P G, McNeal J E, Stamey T A. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol 1995; 153: 111–114
   PubMedGoogle Scholar
• Mandell K, Partin A, Hill G, Epstein J, Stutzman R, Ballentine Carter H, Walsh P. PSA Density in BPH: correlation with stromal epithelial ratios and influence of age. J Urol 1993; 149, suppl. 448A.
   Google Scholar
• Stamey T A, Kabalin J N. Prostate-specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. I. Untreated patients. J Urol 1989; 141: 1070–1075
   PubMed Web of Science ®Google Scholar
• Partin A W, Yoo J, Carter H B, Pearson J D, Chan D W, Epstein J I, Walsh P C. Use of Prostate Specific Antigen, clinical stage, and Gleason score to predict pathological stage in men with localised prostate cancer. J Urol 1993; 150: 110–115
   PubMed Web of Science ®Google Scholar
• Rana A, Chisholm G D. He sold his bike for low prostate specific antigen. J Urol 1994; 151: 700
   PubMed Web of Science ®Google Scholar
• Chybowski F M, Bergstralh E J, Oesterling J E. The effect of digital rectal examination on the serum prostate-specific antigen levels. J Urol 1992; 148: 83–86
   PubMedGoogle Scholar
• Oesterling J E, Rice D C, Glenski W J, Bergstralh E J. Effect of cystoscopy, prostate biopsy, and transurethral resection of the prostate on serum prostate-specific antigen concentration. Urology 1993; 42: 276–282
   PubMed Web of Science ®Google Scholar
• Yuan J J, Coplen D E, Petros J A, Figenshau R S, Ratliff T L, Smith D S, Catalona W J. Effects of rectal examination, prostatic massage, ultrasonography and needle biopsy on serum prostate specific antigen levels. J Urol 1992; 147: 810–811
   PubMed Web of Science ®Google Scholar
• Glenski W J, Klee G G, Bergstralh E J, Oesterling J E. Prostate-specific antigen: establishment of the reference range for the clinically normal prostate gland and the effect of digital rectal examination, ejaculation, and time on serum concentrations. Prostate 1992; 21(2)99–110
   PubMed Web of Science ®Google Scholar
• Dalton D L. Elevated serum prostate-specific antigen due to acute bacterial prostatitis. Urology 1989; 33: 465
   PubMed Web of Science ®Google Scholar
• Oesterling J E. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860–864
   PubMed Web of Science ®Google Scholar
• Collins G N, et al. Ultrasonically determined patterns of enlargement in benign prostatic hyperplasia. Br J Urol 1993; 71: 451–456
   PubMedGoogle Scholar
• Bosch RLJH, Hop WCJ, Niemer AQHJ, Bangma ChrH, Kirkels W J, Schroder F H. Parameters of protate volume and shape in a community-based population of men between fifty-five and seventy-four years of age. J Urol 1994; 151: 1501–1505
   Google Scholar
• Catalona W J, Smith D S, Ratlift T L, Dodds K M, Coplen D E, Yuan JJJ, Petros J A, Andriole G L. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Eng J Med 1991; 324: 1156–1161
   PubMed Web of Science ®Google Scholar
• Catalona W J, Richie J P, Ahmann F R, Hudson M A, Scardino P T, Flanigdn R C, de Kemion J B, Ratliff T L, Kavoussi L R, Dalkin B L, Waters W B, MacFarlane M T, Southwick P C. Comparison of digital rectal examination and serum prostate specific antigen in early detection of prostate cancer: results of multicenter clinical trial of 6630 men. J Urol 1994; 151: 1283–1290
   PubMed Web of Science ®Google Scholar
• Babaian R J, Mettlin C, Kane R, Murphy G P, Lee F, Drago J R, et al. Investigators of the American Cancer Society National Prostate Cancer Detection Program: The relationship of prostate-specific antigen to digital rectal examination and transrectal ultrasonography. Cancer 1992; 69: 1195–1200
   PubMed Web of Science ®Google Scholar
• Labrie F, Dupont A, Suburu R, Cusan L, Tremblay M, Gomez J-L, Emond J. Serum prostate specific antigen as pre-screening test for prostate cancer. J Urol 1992; 147: 846–852
   PubMed Web of Science ®Google Scholar
• Partin A W, Pound C R, Clemens J Q, Epstein J I, Walsh P C. Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 1993; 20: 713–725
   PubMed Web of Science ®Google Scholar
• Benson M C, Whang I S, Pantuck A, Ring K, Kaplan S A, Olsson C A, Cooner W H. The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 1992; 147(3)817–821
   PubMedGoogle Scholar
• Kalish J, Adams J A, Cooner W H, Graham S D. Comparison of PSAD and PSAT in benign and malignant prostatic disease. J Urol 1993; 149, suppl:414A.
   Google Scholar
• Bangma ChrH, Grobbee D E, Schriider F H. Volume adjustment for intermediate prostate specific antigen values in a screening population. Accepted for publication in Eur J Cancer 1995
   Google Scholar
• Carter H B, Morrell C H, Pearson J D, Brant L J, Plato C C, Metter E L, Chan D W, Fozard J L, Walsh P C. Estimation of prostatic growth using serial prostate specific antigen measurements in men with and without prostate disease. Cancer Research 1992; 52: 3323–3328
   PubMed Web of Science ®Google Scholar
• Porter J R, Hayward R, Brawer M K. The significance of short-term PSA change in men undergoing ultrasound-guided prostate biopsy. J Uro 1994; 1151(5)293A
   Google Scholar
• Smith D S, Catalona W J. Rate of change in serum prostate specific antigen levels as method for prostate cancer detection. J Urol 1994; 152: 1163–1168
   PubMed Web of Science ®Google Scholar
• Bogdanowicz JFAT, Bentvelsen F M, Oosterom R, Schröder F H. Evaluation of prostate-specific antigen and prostatic acid phosphatase in untreated prostatic carcinoma and benign prostatic hyperplasia. Scand J Urol Nephrol Suppl. 1991; 138: 97–103
   PubMedGoogle Scholar
• Terris M K, McNeal J E, Stamey T A. Estimation of prostate cancer volume by transrectal ultrasound imaging. J Urol 1992; 147: 855–857
   PubMed Web of Science ®Google Scholar
• Shinohara K, Wolf J S, Narayan P, Carroll P R. Comparison of prostate specific antigen with prostate specific antigen density for 3 clinical applications. J Urol 1994; 152: 120–123
   PubMedGoogle Scholar
• Oesterling J E, Martin S K, Bergstralh E L, Lowe F C. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 5764
   Google Scholar
• Bluestein D I, Bostwick D G, Bergstralh E J, Oesterling J E. Eliminating need for bilateral pelvic lymphadenectomy in select patients with prostate cancer. J Urol 1994; 151: 1315–1321
   PubMed Web of Science ®Google Scholar
• Cadeddu J A, Pearson J D, Partin A W. Relationship between changes in prostate-specific antigen and prognosis of men with prostate cancer. Urology 1993; 42: 383–389
   PubMed Web of Science ®Google Scholar
• Semjonow A, Hamm M, Rathert P. Half-life of prostate specific antigen after radical prostatectomy: the decisive predictor of curative treatment ?. Eur Urol 1992; 21: 200–205
   PubMedGoogle Scholar
• Takayama T K, Vessella R L, Brawer M K, True L D, Noteboom J, Lange P H. Urinary prostate specific antigen levels after radical prostatectomy. J Urol 1994; 151: 82–87
   PubMed Web of Science ®Google Scholar
• Willett C G, Zietman A L, Shipley W U. Coen 15 The effect of pelvic radiation therapy on serum levels of specific antigen. J Urol 1994; 151: 1579–1581
   PubMedGoogle Scholar
• Zietman A L, Coen J J, Shipley W U, Willett C G, Efird J T. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994; 151: 640–645
   PubMed Web of Science ®Google Scholar
• Lange P H, Lightner D J, Medini E, Reddy P, Vessella R L. The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol 1990; 144: 927–933
   PubMedGoogle Scholar
• Guess H A, Heyse J F, Gormley G J. The effect of Finasteride on prostate-specific antigen in men with benign prostatic hyperplasia. The Prostate 1993; 22: 31–37
   PubMed Web of Science ®Google Scholar
• Weber J P, Oesterling J E, Peters C A, Partin A W, Chan D W, Walsh P C. The influence of reversible androgen deprivation on serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol 1989; 141: 987–991
   PubMed Web of Science ®Google Scholar
• Stoner E, Round E, Ferguson D, Gormley G. The Finasteride Study Group. Clinical experience of the detection of prostate cancer in patients with benign prostatic hyperplasia treated with Finasteride. J Urol 1994; 151: 1296–1300
   PubMedGoogle Scholar
• Zagars G K, Sands M E, Pollack A, von Eschenbach A C. Early androgen ablation for stage D1 (N1 to N3, MO) prostate cancer: prognostic variables and outcome. J Urol 1994; 151: 1330–1333
   PubMedGoogle Scholar
• Davidson PJT, Hop W, Kurth K H, Fossa S D, Waehre H, Schroder F H. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (T0—4 N1—3 M0, D1). 1994, Accepted for publication in Lancet
   Google Scholar
• Partin A, Pearson J, Pound C. Rate of change of serum prostatic specific antigen (PSA) after radical prostatectomy distinguishes local recurrence from distant metastases. J Urol 1993; 149: 447, abstr. #937
   Google Scholar